

## Z-033 In Vitro Activity of Pradofloxacin against Clinical Isolates from European Field Studies

A.Pridmore<sup>1</sup>, B. Stephan<sup>2</sup>, H.A. Greife<sup>2</sup>, P.Silley<sup>3,1</sup>;

<sup>1</sup>Don Whitley Scientific Limited, Shipley, UNITED KINGDOM, <sup>2</sup>Bayer HealthCare AG Leverkusen, Germany, <sup>3</sup>MB Consult Limited, Bingley, UNITED KINGDOM.

**Background:** Pradofloxacin (PRA) is a novel fluoroquinolone specifically developed for veterinary medicine with enhanced activity against Grampositive bacteria. The purpose of this study was to assess PRA activity against clinical field isolates. **Methods:** Multicentre, multiregional controlled, randomised and blinded clinical field studies were carried out in Belgium, France and Germany with respect to wound, pyoderma, and urinary tract infections in dogs and upper respiratory tract and wound infections and abscesses in cats. Bacteria were isolated and identified in local laboratories and submitted to a central laboratory where identification was confirmed and susceptibility testing carried out. In all cases methodology followed NCCLS guidelines. **Results:** Of the 1276 strains tested, PRA activity against the most common species/genera is listed below showing range, MIC<sub>50</sub>, MIC<sub>90</sub> and geometric mean (GM) MIC data:

Organism	N	Range µg/ml	MIC <sub>50</sub>	MIC <sub>90</sub>	GM
<i>Staph. Intermedius</i>	318	≤0.016 - 4	0.031	0.125	0.04
<i>E.coli</i>	212	≤0.016 - 8	≤0.016	0.125	0.03
<i>Staphylococcus</i> spp.	170	≤0.016 - 4	0.031	0.5	0.07
<i>Pasteurella</i> spp.	139	≤0.016 - 1	≤0.016	≤0.016	0.02
<i>Streptococcus canis</i>	66	0.031 – 0.25	0.062	0.125	0.07
<i>Acinetobacter</i> spp.	39	≤0.016 – 2	≤0.016	0.25	0.03
<i>Enterococcus faecalis</i>	38	≤0.016 – 1	0.25	0.5	0.31
<i>Pseudomonas</i> spp.	36	≤0.016 – 16	0.25	1	0.32
<i>Enterobacter</i> spp.	32	≤0.016 – 1	0.031	0.5	0.05
<i>Proteus</i> spp.	32	0.031 – 4	0.125	0.5	0.17
<i>Klebsiella</i> spp.	29	≤0.016 - 0.125	0.031	0.062	0.03
<i>Flavimonas</i> spp.	26	≤0.016 – 2	0.031	1	0.05
<i>Streptococcus</i> spp.	21	0.031 – 1	0.062	0.25	0.11
<i>Pantoea</i> spp.	20	≤0.016 -0.125	≤0.016	0.031	0.02
<i>Chryseomonas</i> spp.	18	≤0.016 – 1	0.031	0.25	0.05
<i>Sten. maltophilia</i>	17	≤0.016 – 0.5	0.125	0.25	0.09
<i>Serratia</i> spp.	16	≤0.016 – 0.5	≤0.016	0.25	0.03
<i>Aeromonas</i> spp.	15	≤0.016 – 0.5	≤0.016	0.25	0.03
<i>Citrobacter</i> spp.	15	≤0.016 – 0.5	0.031	0.5	0.06
<i>Bordetella</i> spp.	10	0.031 – 0.5	0.25	0.25	0.19
<i>Burkholderia cepacia</i>	7	0.062 – 1	0.062	-	0.1

**Conclusion:** Pradofloxacin is highly active against clinical field isolates.